Business context and reporting period
The supplied filing is BioSante Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2012. This does not match the request metadata identifying ANI Pharmaceuticals, Inc.; verify the company and filing before relying on this summary.
BioSante was a development-stage specialty pharmaceutical company focused on female sexual health and oncology. Its portfolio included LibiGel, GVAX cancer vaccines, The Pill-Plus, and licensed products Elestrin and a male testosterone gel. The male gel received FDA approval in February 2012; Teva was its licensee.
Financial results and position
| Metric | Q1 2012 | Q1 2011 / prior date |
|---|---|---|
| Revenue | $114,000 | $57,000 |
| Research and development expense | $5.18 million | $14.86 million |
| General and administrative expense | $1.83 million | $1.59 million |
| Net loss | $10.26 million | $17.25 million |
| Basic and diluted loss per share | $0.09 | $0.20 |
| Net cash used in operations | $7.69 million | $10.47 million |
| Cash and cash equivalents | $49.47 million | $57.23 million at Dec. 31, 2011 |
| Total liabilities | $16.58 million | $24.56 million at Dec. 31, 2011 |
Q1 2012 investing cash use was $62,189; financing cash flow was zero, versus $23.89 million provided by financing in Q1 2011. Current assets were $50.19 million and current liabilities $6.08 million at quarter-end. Outstanding 3.125% convertible notes had $11.78 million principal due May 1, 2013; their recorded fair value was $10.49 million. The filing reports no material off-balance-sheet arrangements. Revenue consisted of Elestrin royalties and was offset by an equal royalty obligation to Antares. Gross margin is not presented and is not meaningful from the supplied data.
Material changes versus the prior comparable period
- Revenue doubled from a small base. R&D expense fell 65%, primarily because the two LibiGel Phase III efficacy trials ended in 2011. Net loss narrowed by about 41%.
- G&A expense rose 15%, attributed to personnel, professional fees, and other administrative costs.
- The company issued approximately 11.2 million shares to cancel $9.0 million of note principal and accrued interest. This reduced note principal from $20.78 million at year-end to $11.78 million and increased shares outstanding.
- Reported results included a $3.21 million convertible-note fair-value adjustment, including a noncash adjustment associated with the debt exchange. The adjustment materially affected the reported loss.
Outlook, risks, and unusual items
- Management expected March 31 cash to fund liquidity needs through mid-2013, absent significant licensing income or financing, while warning estimates could prove incorrect. It expected to spend about $2.0 million per month on R&D for the rest of 2012 if the LibiGel safety study continued; spending could be minimal if it stopped and no new development projects were added.
- LibiGel’s two pivotal Phase III efficacy trials did not meet their co-primary or secondary endpoints. Management planned to decide in Q2 2012 whether to continue the safety study. The independent monitoring committee recommended continuing it; the company reported 3,656 participants and more than 5,800 subject-years of exposure. A primary safety analysis was expected in the second half of 2012 if the study continued.
- The company expected substantial continuing losses and had no credit facility. Additional capital might require dilutive equity, debt, licensing, asset sales, or other strategic transactions. Management warned that insufficient financing could force further cost cuts, a sale or merger, or winding down operations.
- The notes mature in May 2013. The company also reported Nasdaq minimum-bid-price noncompliance, with a July 30, 2012 deadline to regain compliance; a reverse split was under consideration as a possible remedy. Stockholders had approved no reverse split at the time described.
- A purported securities class action and a shareholder derivative suit related to LibiGel disclosures were pending. The company disputed the claims but could not estimate an outcome or potential loss. The derivative suit was filed May 7, 2012, after quarter-end.
- A gel-filling-machine purchase commitment had $505,644 remaining at March 31. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing issuer: the source is BioSante Pharmaceuticals, Inc., not ANI Pharmaceuticals, Inc.
- Check subsequent disclosures on the LibiGel safety-study decision and results, and any changes to the company’s development strategy.
- Assess cash burn, the stated mid-2013 liquidity horizon, financing alternatives, and the May 2013 note maturity.
- Verify Nasdaq listing status and any reverse-split action, as well as dilution from equity awards and debt exchanges.
- Review subsequent developments in the securities and derivative litigation and any disclosed financial exposure.